Nivalis Therapeutics Company Profile (NASDAQ:ALPN)

About Nivalis Therapeutics (NASDAQ:ALPN)

Nivalis Therapeutics logoNivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company's S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company's lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALPN
  • CUSIP: N/A
  • Web: www.nivalis.com
Capitalization:
  • Market Cap: $46.38 million
  • Outstanding Shares: 666,000
Average Prices:
  • 50 Day Moving Avg: $10.84
  • 200 Day Moving Avg: $9.71
  • 52 Week Range: $7.20 - $30.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.84
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.95 million
  • Price / Sales: 2.49
  • Book Value: ($10.09) per share
  • Price / Book: -1.09
Profitability:
  • EBITDA: ($6,840,000.00)
  • Return on Equity: -50.95%
  • Return on Assets: -46.61%
Debt:
  • Current Ratio: 13.90%
  • Quick Ratio: 13.90%
Misc:
  • Average Volume: 41,014 shs.
  • Beta: 0.15
  • Short Ratio: 3.51
 

Frequently Asked Questions for Nivalis Therapeutics (NASDAQ:ALPN)

What is Nivalis Therapeutics' stock symbol?

Nivalis Therapeutics trades on the NASDAQ under the ticker symbol "ALPN."

How were Nivalis Therapeutics' earnings last quarter?

Nivalis Therapeutics, Inc. (NASDAQ:ALPN) posted its quarterly earnings data on Monday, February, 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.05. During the same quarter in the prior year, the firm earned ($0.42) earnings per share. View Nivalis Therapeutics' Earnings History.

Where is Nivalis Therapeutics' stock going? Where will Nivalis Therapeutics' stock price be in 2017?

6 brokers have issued twelve-month price objectives for Nivalis Therapeutics' stock. Their forecasts range from $3.00 to $17.00. On average, they expect Nivalis Therapeutics' share price to reach $7.31 in the next twelve months. View Analyst Ratings for Nivalis Therapeutics.

What are analysts saying about Nivalis Therapeutics stock?

Here are some recent quotes from research analysts about Nivalis Therapeutics stock:

  • 1. According to Zacks Investment Research, "Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. " (8/10/2017)
  • 2. Cowen and Company analysts commented, "This evening Nivalis and Alpine Immune Sciences announced an agreement to merge." (4/19/2017)

Who are some of Nivalis Therapeutics' key competitors?

Who are Nivalis Therapeutics' key executives?

Nivalis Therapeutics' management team includes the folowing people:

  • Howard P. Furst M.D., Chairman of the Board
  • R. Michael Carruthers, Interim President, Chief Financial Officer, Secretary
  • Janice M. Troha, Chief Operating Officer
  • Sherif Gabriel Ph.D., Vice President – Research and Discovery
  • Steven Shoemaker M.D., Vice President – Clinical Research and Development, Medical Director
  • Robert E. Conway, Independent Director
  • Evan Loh M.D., Independent Director
  • John R. Moore, Independent Director
  • Paul Sekhri, Independent Director

How do I buy Nivalis Therapeutics stock?

Shares of Nivalis Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nivalis Therapeutics' stock price today?

One share of Nivalis Therapeutics stock can currently be purchased for approximately $11.03.


MarketBeat Community Rating for Nivalis Therapeutics (NASDAQ ALPN)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Nivalis Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nivalis Therapeutics (NASDAQ:ALPN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $7.31 (33.70% downside)
Consensus Price Target History for Nivalis Therapeutics (NASDAQ:ALPN)
Price Target History for Nivalis Therapeutics (NASDAQ:ALPN)
Analysts' Ratings History for Nivalis Therapeutics (NASDAQ:ALPN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$17.00LowView Rating Details
4/19/2017Cowen and CompanyReiterated RatingHoldMediumView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$30.00 -> $6.00N/AView Rating Details
11/29/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
11/29/2016Robert W. BairdDowngradeOutperform -> Neutral$29.00 -> $3.00N/AView Rating Details
11/29/2016Stifel NicolausDowngradeBuy -> Hold$16.00 -> $3.25N/AView Rating Details
8/30/2016Piper Jaffray CompaniesReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Nivalis Therapeutics (NASDAQ:ALPN)
Earnings by Quarter for Nivalis Therapeutics (NASDAQ:ALPN)
Earnings History by Quarter for Nivalis Therapeutics (NASDAQ ALPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2017Q4 16($0.55)($0.50)ViewN/AView Earnings Details
11/7/2016Q3($0.59)($0.48)ViewN/AView Earnings Details
8/1/2016Q2($0.52)($0.55)ViewN/AView Earnings Details
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details
2/29/2016Q4 15($0.36)($0.42)ViewN/AView Earnings Details
11/2/2015Q3 15($0.39)($0.39)ViewN/AView Earnings Details
8/3/2015Q2 2015($0.40)($1.41)ViewN/AView Earnings Details
4/18/2012$0.61$0.61ViewN/AView Earnings Details
2/2/2012$0.47$0.73ViewN/AView Earnings Details
10/26/2011$0.68$0.73ViewN/AView Earnings Details
7/11/2011$0.77$0.79ViewN/AView Earnings Details
4/27/2011$1.03$1.04ViewN/AView Earnings Details
1/31/2011$0.94$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nivalis Therapeutics (NASDAQ:ALPN)
Current Year EPS Consensus Estimate: $-3.11 EPS
Next Year EPS Consensus Estimate: $-2.28 EPS

Dividends

Dividend History for Nivalis Therapeutics (NASDAQ:ALPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nivalis Therapeutics (NASDAQ:ALPN)
Insider Ownership Percentage: 9.80%
Insider Trades by Quarter for Nivalis Therapeutics (NASDAQ:ALPN)
Insider Trades by Quarter for Nivalis Therapeutics (NASDAQ:ALPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/20/2017Value Fund L P BiotechnologyInsiderBuy17,806$2.25$40,063.50View SEC Filing  
6/7/2017Bvf Partners L P/IlMajor ShareholderBuy36,900$2.28$84,132.00View SEC Filing  
6/7/2017Value Fund L P BiotechnologyInsiderBuy72,650$2.29$166,368.50View SEC Filing  
6/5/2017Bvf Partners L P/IlMajor ShareholderBuy35,750$2.29$81,867.50View SEC Filing  
5/31/2017Value Fund L P BiotechnologyInsiderBuy47,000$2.27$106,690.00View SEC Filing  
5/19/2017Value Fund L P BiotechnologyInsiderBuy78,858$2.30$181,373.40View SEC Filing  
5/11/2017Value Fund L P BiotechnologyInsiderBuy109,034$2.32$252,958.88View SEC Filing  
5/9/2017Robert E ConwayDirectorBuy5,000$2.34$11,700.00View SEC Filing  
5/8/2017Robert E ConwayDirectorBuy15,000$2.28$34,200.00View SEC Filing  
5/5/2017Janice TrohaEVPBuy10,000$2.34$23,400.00View SEC Filing  
5/5/2017Robert E ConwayDirectorBuy20,000$2.30$46,000.00View SEC Filing  
5/4/2017Robert E ConwayDirectorBuy10,000$2.26$22,600.00View SEC Filing  
1/4/2017David Malcom RodmanEVPSell6,687$2.27$15,179.49View SEC Filing  
12/2/2016R Michael CarruthersEVPBuy24,000$2.09$50,160.00View SEC Filing  
10/4/2016David Malcom RodmanEVPSell5,820$7.96$46,327.20View SEC Filing  
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.00View SEC Filing  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.00View SEC Filing  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.00View SEC Filing  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.00View SEC Filing  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.00View SEC Filing  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.00View SEC Filing  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nivalis Therapeutics (NASDAQ:ALPN)
Latest Headlines for Nivalis Therapeutics (NASDAQ:ALPN)
Source:

Social

Chart

Nivalis Therapeutics (ALPN) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.